[go: up one dir, main page]

AR067877A1 - Compuestos de pirimidina - Google Patents

Compuestos de pirimidina

Info

Publication number
AR067877A1
AR067877A1 ARP080103456A ARP080103456A AR067877A1 AR 067877 A1 AR067877 A1 AR 067877A1 AR P080103456 A ARP080103456 A AR P080103456A AR P080103456 A ARP080103456 A AR P080103456A AR 067877 A1 AR067877 A1 AR 067877A1
Authority
AR
Argentina
Prior art keywords
co2r3
coor3
hal
denotes
nr3con
Prior art date
Application number
ARP080103456A
Other languages
English (en)
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab filed Critical Serono Lab
Publication of AR067877A1 publication Critical patent/AR067877A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Los compuestos son utiles, por ejemplo, en el tratamiento de trastornos autoinmunes, como, por ejemplo, la esclerosis multiple. Reivindicacion 1: Compuestos de acuerdo con la Formula (1) en donde: X es NRaRb,.SRb o Hal, Ra es H o A, Rb es A, A es alquilo lineal o ramificado que posee 1 a 12 átomos de carbono, en donde uno o más, con preferencia 1 a 7 átomos de H se pueden reemplazar por Hal, OR3, COOR3, CN o N(R3)2 y en donde uno o más, con preferencia 1 a 7 grupos CH2 no adyacentes se pueden reemplazar por O, NR3, S o SO2 y/o por grupos -CH=CH-, o denota cicloalquilo o cicloalquilalquileno que posee 3-7 átomos de C anulares; Hal es F, Cl, Br o I, W es C=O, C=S, SO2 o SO, Q es NR3, -O- o -S-, R es H, A, Ar, Het, Ar denota un anillo carbocíclico monocíclico o bicíclico, saturado, insaturado o aromático que posee 6 a 14 átomos de carbono, que puede estar no sustituido o monosustituido, disustituido o trisustituido por Hal, A, OR3, -[C(R3)2]n-OR3, N(R3)2, -[C(R3)2]n-N(R3)2, NO2, CN, COOR3, CF3, OCF3, CON(R3)2, NR3COA, NR3CON(R3)2, -[C(R3)2]n-, Het, -[C(R3)2]n-Ar, -[C(R3)2]n-cicloalkil, -[C(R3)2]n-, CON(R3)2, -[C(R3)2]n-COOR3, -[C(R3)2]-NR3-[C(R3)2]-CO2R3, -[C(R3)2]n-NR3-[C(R3)2]n-OR3, -SO2-[C(R3)2]n-CO2R3, -SO2- -N(R3)2-[C(R3)2]n-CO2R3, -[C(R3)2]-SO2-[C(R3)2]-CO2R3, -SO2-, [C(R3)2]n-OR3, -SO2-N(R3)2-[C(R3)2]n-OR3, -SO2-, [C(R3)2]n-OR3, -SO2-N(R3)2-[C(R3)2]n-OR3, -[C(R3)2]n-SO2-, [C(R3)2]n-OR3, NR3CON(R3)2, NR3SO2A, COR3, SO2N(R3)2, SO2N(R3)A, SOA, SONR3A, o SO2A, y/o -O[C(R3)2]n-COOR3, Het denota un anillo heterocíclico, nomocíclico o bicíclico, saturado, insaturado o aromático que posee 1 a 4 átomos de N, O y/o S que puede estar no sustituido o monosustituido, disustituido o trisustituido por Hal, A, OR3, -[C(R3)2]n-OR3, N(R3)2, -[C(R3)2)n-N(R3)2, NO2, CN, COOR3, CF3, OCF3, CON(R3)2, NR3COA, NR3CON(R3)2, -[C(R3)2]n-Het, -[C(R3)2]n-Ar, -[C(R3)2]n-cicloalkil, -[C(R3)2]n-CON(R3)2, -[C(R3)2]n-COOR3, -[C(R3)2]-NR3-[C(R3)2]n-CO2R3, -[C(R3)2]-NR3-[C(R3)2]n-OR3, -SO2-[C(R3)2]n-CO2R3, -SO2-, N(R3)2-[C(R3)2]n-CO2R3, -[C(R3)2]n-SO2-[C(R3)2]n-CO2R3, -SO2- [C(R3)2]n-OR3, -SO2-N(R3)2-[C(R3)2]n-OR3, -[C(R3)2]n-SO2-, [C(R3)2]n-OR3, NR3CON(R3)2, NR3SO2A, COR3, SO2N(R3)2, SO2N(R3)A, SOA, SONR3A, o SO2A, y/o -O[C(R3)2]-COOR3, R1 denota A o H, R2 denota H, A o HAL R3 es H o A n es 0, 1, 2, 3, 4, 5, 6, 7 o 8, y sus derivados, solvatos, tautomeros, sales y estereoisomeros farmacéuticamente aceptables, con inclusion de sus mezclas en todas las relaciones.
ARP080103456A 2007-08-08 2008-08-07 Compuestos de pirimidina AR067877A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07113992 2007-08-08
US96486407P 2007-08-15 2007-08-15

Publications (1)

Publication Number Publication Date
AR067877A1 true AR067877A1 (es) 2009-10-28

Family

ID=38985492

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080103456A AR067877A1 (es) 2007-08-08 2008-08-07 Compuestos de pirimidina

Country Status (15)

Country Link
US (2) US8399448B2 (es)
EP (1) EP2183224B1 (es)
JP (1) JP5508265B2 (es)
KR (1) KR20100051849A (es)
CN (1) CN101790519B (es)
AR (1) AR067877A1 (es)
AU (1) AU2008285722B2 (es)
BR (1) BRPI0814975A2 (es)
CA (1) CA2696565C (es)
EA (1) EA201070238A1 (es)
ES (1) ES2445405T3 (es)
IL (1) IL203578A (es)
MX (1) MX2010001446A (es)
WO (1) WO2009019167A1 (es)
ZA (1) ZA201000585B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2360929T3 (es) * 2007-09-20 2011-06-10 Amgen Inc. Derivados del ácido 1-(4-(4-bencilbenzamido)-bencil)azetidin-3-carboxílico y compuestos relacionados como moduladores del receptor s1p para el tratamiento de trastornos inmunitarios.
KR20200117058A (ko) 2008-07-23 2020-10-13 아레나 파마슈티칼스, 인크. 자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[ｂ]인돌-3-일)아세트산 유도체
SI2342205T1 (sl) 2008-08-27 2016-09-30 Arena Pharmaceuticals, Inc. Substituirani triciklični kislinski derivati kot agonisti S1P1 receptorja, uporabni v zdravljenju avtoimunskih in vnetnih obolenj
US9073888B2 (en) 2009-10-23 2015-07-07 Allergan, Inc. Coumarin compounds as receptor modulators with therapeutic utility
JP5856980B2 (ja) 2010-01-27 2016-02-10 アリーナ ファーマシューティカルズ， インコーポレイテッド （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス
SG183416A1 (en) 2010-03-03 2012-09-27 Arena Pharm Inc Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
EP2547662A4 (en) * 2010-03-17 2013-10-02 Glaxo Group Ltd PYRIMIDINE DERIVATIVES FOR USE AS AGONISTS OF SPHINGOSIN 1-PHOSPHATE 1 (S1P1) RECEPTORS
CN103619828A (zh) * 2011-04-14 2014-03-05 阿勒根公司 作为1-磷酸鞘氨醇受体调节剂的苯基双环甲基胺衍生物
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2014130572A1 (en) * 2013-02-21 2014-08-28 Allergan, Inc. Substituted 6-methoxy-4-amino-n-phenyl-2-naphtamides as sphingosine receptor modulators
CN103408501B (zh) * 2013-08-14 2016-03-09 合肥医工医药有限公司 苄基嘧啶衍生物、其制备方法及其医药用途
TWI667233B (zh) * 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
CA2935880A1 (en) 2014-01-10 2015-07-16 Aurigene Discovery Technologies Limited Indazole compounds as irak4 inhibitors
EP3466955B1 (en) 2014-01-13 2020-12-16 Aurigene Discovery Technologies Limited Method of preparing oxazolo[4,5-b]pyridine and thiazolo[4,5-b]pyridine derivatives as irak4 inhibitors for treating cancer
KR101499007B1 (ko) * 2014-04-24 2015-03-05 고려대학교 산학협력단 염증성 질환의 예방 또는 치료용 약학 조성물
EP4445956A3 (en) 2015-01-06 2024-12-04 Arena Pharmaceuticals, Inc. Compound for use in treating conditions related to the s1p1 receptor
PL3310760T3 (pl) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
CN115819417A (zh) 2016-09-09 2023-03-21 因赛特公司 作为hpk1调节剂的吡唑并吡啶衍生物及其用于治疗癌症的用途
US10280164B2 (en) 2016-09-09 2019-05-07 Incyte Corporation Pyrazolopyridone compounds and uses thereof
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
US20180072741A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
US20180228786A1 (en) 2017-02-15 2018-08-16 Incyte Corporation Pyrazolopyridine compounds and uses thereof
MA47504A (fr) 2017-02-16 2019-12-25 Arena Pharm Inc Composés et méthodes de traitement de l'angiocholite biliaire primitive
MX2019009843A (es) 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la enfermedad inflamatoria intestinal con manifestaciones extraintestinales.
BR112019018991A2 (pt) 2017-03-31 2020-04-14 Aurigene Discovery Technologies Limited compostos e composições para tratar distúrbios hematológicos
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
EP4410377A3 (en) 2017-10-31 2024-11-13 Curis, Inc. Compounds and compositions for treating hematological disorders
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
DK3755703T3 (da) 2018-02-20 2022-06-27 Incyte Corp N-(phenyl)-2-(phenyl)pyrimidin-4-carboxamidderivater og relaterede forbindelser som hpk1-inhibitorer til behandling af kræft
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
ES2987794T3 (es) 2018-06-06 2024-11-18 Arena Pharm Inc Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
CN119751336A (zh) 2018-09-06 2025-04-04 艾尼纳制药公司 可用于治疗自身免疫性病症和炎性病症的化合物
ES2973117T3 (es) 2018-09-25 2024-06-18 Incyte Corp Compuestos de pirazolo[4,3-d]pirimidina como moduladores de ALK2 y/o FGFR
JP2022543155A (ja) 2019-08-06 2022-10-07 インサイト・コーポレイション Ｈｐｋ１阻害剤の固体形態
JP2023503470A (ja) * 2019-11-25 2023-01-30 ゲイン セラピューティクス エスアー ガラクトセレブロシダーゼの活性の変質に関連する状態におけるアリールおよびヘテロアリール化合物、ならびにそれらの治療的使用
US12178821B2 (en) 2021-04-08 2024-12-31 Curis, Inc. Combination therapies for the treatment of cancer
GB202213310D0 (en) * 2022-09-12 2022-10-26 Benevolentai Cambridge Ltd New compounds and methods
WO2024126777A1 (en) * 2022-12-16 2024-06-20 Astrazeneca Ab Heteroaromatic compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9913947A (pt) * 1998-09-25 2001-06-12 Astrazeneca Ab Derivado de amida, processo para a preparação do mesmo ou um sal farmaceuticamente aceitável ou éster clivável in vivo deste, uso do mesmo, e, composição farmacêutica
AU2002314252A1 (en) * 2001-05-28 2002-12-09 Aventis Pharma S.A. Chemical derivatives and the use thereof as an anti-telomerase agent
AU2003245555A1 (en) * 2002-06-17 2003-12-31 The Pennsylvania State Research Foundation Sphingosine kinase inhibitors
TW200524880A (en) * 2003-10-21 2005-08-01 Sankyo Co Pyrimidine compounds
ES2308299T3 (es) 2003-12-19 2008-12-01 Schering Corp Tiadiazoles como ligandos de receptores de cxc-y cc-quimioquinas.
WO2006053109A1 (en) * 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Heteroaryl compounds
AR067354A1 (es) * 2007-06-29 2009-10-07 Sunesis Pharmaceuticals Inc Compuestos utiles como inhibidores de la raf quinasa

Also Published As

Publication number Publication date
US20130109669A1 (en) 2013-05-02
EP2183224B1 (en) 2013-11-06
US9150519B2 (en) 2015-10-06
CN101790519B (zh) 2013-10-16
AU2008285722A1 (en) 2009-02-12
JP2010535734A (ja) 2010-11-25
AU2008285722B2 (en) 2013-06-20
US20100210619A1 (en) 2010-08-19
JP5508265B2 (ja) 2014-05-28
IL203578A (en) 2014-02-27
ES2445405T3 (es) 2014-03-03
ZA201000585B (en) 2011-04-28
EA201070238A1 (ru) 2010-08-30
EP2183224A1 (en) 2010-05-12
BRPI0814975A2 (pt) 2015-02-03
WO2009019167A1 (en) 2009-02-12
CA2696565C (en) 2017-02-14
CN101790519A (zh) 2010-07-28
US8399448B2 (en) 2013-03-19
KR20100051849A (ko) 2010-05-18
CA2696565A1 (en) 2009-02-12
MX2010001446A (es) 2010-03-01

Similar Documents

Publication Publication Date Title
AR067877A1 (es) Compuestos de pirimidina
AR068731A1 (es) Compuestos de diaril 1,2,4-oxadiazol,composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos como agentes inmunosupresores en el tratamiento de enfermedades autoinmunes y/o inflamatorias cronicas.
AR076187A1 (es) Derivados de oxadiazol, proceso de preparacion de los mismos y composicion farmaceutica que los contienen
AR076984A1 (es) Derivados de pirazol oxadiazol
AR020851A2 (es) Compuestos macrolidos, composiciones y su uso para la preparacion de medicamentos
AR074700A1 (es) Derivados heterociclicos fusionados con oxadiazola, composiciones farmaceuticas, procesos de preparacion y su uso en el tratamiento de esclerosis multiple y otras enfermedades
AR087196A1 (es) Metodos plaguicidas que utilizan compuestos de 3-piridil tiazol sustituido y derivados para combatir las plagas de animales ii
UY26727A1 (es) Derivados de tropano útiles en terapia
AR061994A1 (es) Uso de derivados de imidazol activadores de ampk, su proceso de preparacion y composiciones farmaceuticas que los comprenden
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
PA8491901A1 (es) Procedimientos e intermedios para preparar compuestos anticancerosos.
AR037983A1 (es) Derivados de pirido [2,1-a] isoquinolina
AR075635A1 (es) N-alcoxiamidas de 6-(fenil sustituido)-4-aminopicolinatos y 2-(fenil sustituido)-6-amino-4-pirimidina carboxilatos, su uso como herbicidas selectivos para las cosechas y proceso de preparacion de dichos compuestos
ECSP066855A (es) Derivados de benceno sustituidos por glucopiranosilo, medicamentos que contienen esos compuestos, su aplicación y procedimiento para su preparación
AR071285A1 (es) Pirido[3, 4-b]indoles, una composicion farmaceutica que los comprende y su uso en el tratamiento de trastornos neurologicos.
AR059428A1 (es) Pirazoles para el tratamiento de enfermedades mediadas por la modulacion de los receptores de histamina h3 y una composicion farmaceutica que los comprende.
AR066972A1 (es) Derivados azapeptidicos
DOP2010000022A (es) Derivados de pirimidina 934
PE20060937A1 (es) Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2)
PE20080378A1 (es) Derivados tiofeno-pirazolalcanamida con actividad sobre los receptores ampa
AR081828A1 (es) Compuestos de biguanida y su uso para el tratamiento del cancer
CO6150150A2 (es) Derivados de 7-alquinil-1,8-naftiridonas su prepacion y su aplicacion en terapeutica
AR039927A1 (es) Derivados de isoindolona, proceso de preparacion y compuestos intermedios de este proceso, su uso como medicamentos, y composiciones farmaceuticas que los contienen
AR075394A1 (es) Derivados del acido fenoxiacetico, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades inflamatorias,alergicas y neurodegenerativas.
PE20050292A1 (es) Derivados de acido alcanoico sustituidos con aril-cicloalquilo, procedimientos para su obtencion y su empleo como medicamentos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal